Introduction {#s1}
============

MicroRNAs (miRNAs) are a class of endogenous, small nonprotein-coding single-stranded RNA molecules of ∼22 nucleotides in length that regulate a broad range of biologic and pathologic processes [@pone.0050966-Ambros1], [@pone.0050966-Bartel1]. Mature miRNAs regulate the expression of approximately 30% of all human genes involved in fundamental biological processes at post-transcriptional level by sequence-specific binding to 3′ untranslated regions (UTRs) of multiple target messenger RNAs (mRNAs), leading to their degradation or translational suppression [@pone.0050966-Bartel2]. To date, more than 1200 miRNA sequences have been identified in humans, although specific functions have not yet been delineated for most of them.

Cancer is eventually an outcome of chaotic expression of genes involved in developmental, cell growth and differentiation processes. Recent studies have implicated miRNAs in the genesis, progression (proliferation, migration and invasion) and prognosis of multiple human malignancies [@pone.0050966-Garzon1], including their key role in promoting cancer stem cell tumorigenicity [@pone.0050966-Jia1]. Variations in the level of expression of distinct miRNAs ("Oncomirs") have been observed in the development and progression of multiple human cancers and \>50% of these miRNA genes are found to be located in cancer-related chromosomal regions functioning either as oncogenes or tumor suppressor genes [@pone.0050966-Lu1]--[@pone.0050966-EsquelaKerscher1]. Thus, variations in miRNA expression may promote carcinogenesis by modulating the expression patterns of essential genes involved in tumor growth and progression [@pone.0050966-Wiemer1].

Single nucleotide polymorphisms (SNPs) are the most common form of variation present in the human genome. SNPs present in the miRNA gene regions can alter their expression and/or maturation leading to aberrant miRNA regulation. Many epidemiological studies have examined the association of SNPs in microRNAs with cancer susceptibility ([Table 1](#pone-0050966-t001){ref-type="table"}). However, due to power considerations in single SNP studies with relatively small sample sizes, the outcomes of these studies remain contradictory rather than convincing. The present article applied a meta-analytic approach for relevant miRNA SNPs to better clarify potential associations between these SNPs and cancer. We also systematically reviewed published meta-analyses of observational studies investigating the association between miRNA polymorphisms and cancer risk to investigate their strengths and limitations.

10.1371/journal.pone.0050966.t001

###### Characteristics of eligible studies in meta-analysis.

![](pone.0050966.t001){#pone-0050966-t001-1}

  S.no.                                    Reference                                    PublicationYear   Country origin   Ethnicity   Cancer Type   N (cases)   N (controls)   Control source        Genotyping method        HWE        Matching criteria
  ------- ---------------------------------------------------------------------------- ----------------- ---------------- ----------- ------------- ----------- -------------- ---------------- ----------------------------- ----- -----------------------------
  1                              Xu et al., [@pone.0050966-Xu2]                              2008             China          Asian         HCC          479          504              HB                  PCR-RFLP             Yes             age/sex
  2                              Hu et al., [@pone.0050966-Hu2]                              2009             China          Asian         BC          1009          1093             PB                  PCR-RFLP             Yes            age/area
  3                      Jazdzewski et al., [@pone.0050966-Jazdzewski1]                      2008              USA         Caucasian       PTC          608          901              PB                 Sequencing            Yes               NR
  4                            Tian et al., [@pone.0050966-Tian2]                            2009             China          Asian         LC          1058          1035             PB                  PCR-RFLP             Yes          age/sex/area
  5             Ye et al., [@pone.0050966-Ye1] [\*](#nt102){ref-type="table-fn"}             2008              USA         Caucasian       EC           346          346              HB                   SNPlex              Yes             age/sex
  6                         Catucci et al., [@pone.0050966-Catucci1]                         2010             Italy        Caucasian       BC          1894          2760             PB            TaqMan and sequencing      Yes               age
  7        Hoffman et al., [@pone.0050966-Hoffman1] [\$](#nt103){ref-type="table-fn"}        2009              USA         Caucasian       BC           441          479            HB/PB             SequenomMassARRAY        Yes               age
  8                            Peng et al., [@pone.0050966-Peng1]                            2010             China          Asian         GC           213          213              HB                  PCR-RFLP             Yes             age/sex
  9                            Zhou et al., [@pone.0050966-Zhou2]                            2010             China          Asian         CC           703          713              PB                  PCR-RFLP             Yes            age/area
  10                           Yang et al., [@pone.0050966-Yang2]                            2010            Germany       Caucasian       BC          1217          1422             PB            TaqMan and sequencing      Yes               age
  11                             Xu et al., [@pone.0050966-Xu4]                              2010             China          Asian         PC           251          280              HB                  PCR-RFLP             Yes               age
  12                             Qi et al., [@pone.0050966-Qi1]                              2010             China          Asian         HCC          361          391              HB                   PCR-LDR             Yes               NR
  13                            Dou et al., [@pone.0050966-Dou1]                             2010             China          Asian       Glioma         670          680              HB                  PCR-RFLP             Yes          age/sex/area
  14                             Xu et al., [@pone.0050966-Xu5]                              2011             China          Asian         HCC          501          548              PB                  PCR-RFLP             Yes          age/sex/area
  15                            Kim et al., [@pone.0050966-Kim2]                             2010             Korea          Asian         LC           654          640              HB                  PCR-FRET             Yes             age/sex
  16                    Christensen et al., [@pone.0050966-Christensen1]                     2010              USA         Caucasian      HNSCC         484          555              PB                   TaqMan              Yes          age/sex/area
  17                     Srivastava et al., [@pone.0050966-Srivastava1]                      2010             India        Caucasian       GBC          230          230              PB                  PCR-RFLP             Yes             age/sex
  18                            Liu et al., [@pone.0050966-Liu1]                             2010              USA         Caucasian      HNSCC        1109          1130             HB                  PCR-RFLP             Yes             age/sex
  19                           Zeng et al., [@pone.0050966-Zeng1]                            2010             China          Asian         GC           304          304              HB                  PCR-RFLP             Yes             age/sex
  20                            Sun et al., [@pone.0050966-Sun1]                             2010             China          Asian         GC           304          304              HB                  PCR-RFLP             Yes             age/sex
  21                            Guo et al., [@pone.0050966-Guo2]                             2010             China          Asian        ESCC          444          468              HB                  SNaPshot             Yes          age/sex/area
  22                           Yang et al., [@pone.0050966-Yang3]                            2011            Germany       Caucasian       BC          2854          3188             PB         MALDI-TOF mass spectrometry   Yes               age
  23            Li et al., [@pone.0050966-Li2] [\#](#nt104){ref-type="table-fn"}             2010             China          Asian         HCC          310          222              HB                  PCR-RFLP             Yes               NR
  24                        Okubo et al., [@pone.0050966-Okubo1] ^@^                         2010             Japan          Asian         GC           552          697              HB                  PCR-RFLP             Yes               NR
  25                           Chen et al., [@pone.0050966-Chen1]                            2011             China          Asian         CRC          126          407              HB                   PCR-LDR             Yes             age/sex
  26                            Yue et al., [@pone.0050966-Yue1]                             2011             China          Asian         CC           447          443              HB                  PCR-RFLP             Yes               age
  27                         Mittal et al., [@pone.0050966-Mittal1]                          2011             India        Caucasian       UBC          212          250              HB                  PCR-RFLP             Yes             age/sex
  28                           Zhou et al., [@pone.0050966-Zhou3]                            2011             China          Asian         CC           226          309              HB                  PCR-RFLP             Yes               age
  29                          Akkiz et al., [@pone.0050966-Akkiz1]                           2011             Turkey       Caucasian       HCC          185          185              HB                  PCR-RFLP             Yes     age/sex/smoking/alcohol
  30                           Zhan et al., [@pone.0050966-Zhan1]                            2011             China          Asian         CRC          252          543              HB                  PCR-RFLP             Yes             age/sex
  31                           Hong et al., [@pone.0050966-Hong1]                            2011             Korea          Asian        NSCLC         406          428              PB                   TaqMan              Yes             age/sex
  32                    Permuth-Wey et al., [@pone.0050966-PermuthWey1]                      2011              USA         Caucasian     Glioma         593          614              PB            Illumina's GoldenGate      Yes               NR
  33                          Akkiz et al., [@pone.0050966-Akkiz2]                           2011             Turkey       Caucasian       HCC          222          222              HB                  PCR-RFLP             Yes     age/sex/smoking/alcohol
  34                            Zhu et al., [@pone.0050966-Zhu1]                             2011             China          Asian         CRC          573          588              HB                   TaqMan              Yes             age/sex
  35                           Zhou et al., [@pone.0050966-Zhou1]                            2011             China          Asian         HCC          186          483              HB                  PCR-RFLP             Yes               NR
  36                        Schuetz et al., [@pone.0050966-Schuetz1]                         2012             Canada       Caucasian       NHL          717          694              PB            Illumina's GoldenGate      Yes          age/sex/area
  37                          Xiang et al., [@pone.0050966-Xiang1]                           2012             China          Asian         HCC          100          100              HB                  PCR-RFLP             Yes               NR
  38                      Jedlinski et al., [@pone.0050966-Jedlinski1]                       2011           Australia      Caucasian       BC           193          190              PB                  PCR-RFLP             Yes               age
  39          Yang et al., [@pone.0050966-Yang1] [\*](#nt102){ref-type="table-fn"}           2008              USA         Caucasian       UBC          746          746              HB                   SNPlex              Yes             age/sex
  40        George et al., [@pone.0050966-George1] [!](#nt106){ref-type="table-fn"}          2011             India        Caucasian       PC           159          230              HB                  PCR-RFLP             Yes             age/sex
  41                           Wang et al., [@pone.0050966-Wang2]                            2010             China          Asian        ESCC          458          489              PB                  SNaPshot             Yes          age/sex/area
  42                          Zhang et al., [@pone.0050966-Zhang1]                           2011             China          Asian         HCC          302          513              HB                  PCR-RFLP             Yes               NR
  43                          Zhang et al., [@pone.0050966-Zhang2]                           2012             China          Asian         BC           252          248              PB                  PCR-RFLP             Yes          age/sex/area
  44                      Pastrello et al., [@pone.0050966-Pastrello1]                       2010             Italy        Caucasian      BC/OC         101          155              NR                 Sequencing            Yes               NR
  45                          Vinci et al., [@pone.0050966-Vinci1]                           2011             Italy        Caucasian      NSCLC         101          129              NR                    HRMA               Yes             age/sex
  46                           Zhou et al., [@pone.0050966-Zhou4]                            2012             China          Asian         GC          1686          1895             HB                   TaqMan              Yes             age/sex
  47                            Kim et al., [@pone.0050966-Kim1]                             2012             Korea          Asian         HCC          159          201              PB                  PCR-RFLP             Yes               NR
  48                          Smith et al., [@pone.0050966-Smith1]                           2012           Australia      Caucasian       BC           193          193              HB                    HRMA               Yes        age/sex/ethnicity
  49                        Hishida et al., [@pone.0050966-Hishida1]                         2011             Japan          Asian         GC           583          540              HB                  PCR-CTPP             Yes             age/sex
  50                       Horikawa et al., [@pone.0050966-Horikawa1]                        2008              USA         Caucasian       RCC          279          278              PB                   SNPlex              Yes   age/sex/ethnicity/residence
  51                           Lung et al., [@pone.0050966-Lung1]                            2012             China          Asian         NPC          233          3786             PB                  Tm-shift             Yes             age/sex
  52           Chu et al., [@pone.0050966-Chu1] [&](#nt107){ref-type="table-fn"}             2012             Taiwan         Asian        OSCC          470          425              HB                  PCR-RFLP             Yes               NR
  53                            Bae et al., [@pone.0050966-Bae1]                             2012             Korea          Asian         HCC          417          404              HB                   TaqMan              Yes               NR

HCC: hepatocellular cancer; BC: breast cancer; GBC: gallbladder cancer; GC: gastric cancer; NSCLC: non-small cell lung carcinoma; CC: cervical cancer; LC: lung cancer; EC: esophageal cancer; PC: prostate cancer; HNSCC: head and neck squamous cell carcinoma; NHL: Non-Hodgkin lymphoma; OC: ovarian cancer; PTC: papillary thyroid carcinoma; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; UBC: urinary bladder cancer; CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; NPC: Nasopharyngeal Carcinoma; OSCC: oral squamous cell carcinoma; HWE: Hardy-Weinberg equilibrium; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR--LDR: polymerase chain reaction--ligation detection reaction; PCR-FRET: polymerase chain reaction--fluorescent resonance energy transfer; HRMA: high-resolution melting analysis; PCR-CTPP: polymerase chain reaction with confronting two-pair primers; Tm-shift: Melting-temperature--shift allele-specific genotyping; HB: hospital based; PB: population based; NR: not reported;

Let7f-2 rs17276588 deviated from HWE in controls.

mir-492 rs2289030 and mir-149 rs2292832 deviated from HWE in controls.

Cirrhosis patients without HCC served as controls.

miR-499 rs3746444 deviated from HWE in controls.

mir196a2 rs11614913 and mir146a rs2910164 deviated from HWE in controls.

miRNA149 rs2292832 deviated from HWE in controls.

Methods {#s2}
=======

Publication Search {#s2a}
------------------

We searched the PubMed, Medline and Embase databases using the search terms "miRNA," "cancer/carcinoma," and "polymorphism/variant" updated until August 25, 2012 and limited to English language papers. Identification of meta-analyses of association studies on miRNA polymorphisms and cancer was also carried out through a search of electronic databases of PubMed, Medline and Embase, up to August 2012. The Medical Subject Headings and key words used for the search were "miRNA", "cancer", "polymorphism", and "meta-analysis" (with both synonymous and plural forms). The online searching was accompanied by checking reference lists from the identified articles and reviews for potentially eligible original reports.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

All miRNA association studies were included in the present meta-analysis if they met the following criteria: 1) case-control study, 2) outcome cancer (histologically/pathologically proven), and 3) sufficient data for examining an odds ratio (OR) with 95% confidence interval (95% CI). The major exclusion criteria were as follows: 1) duplicate data, 2) case reports, series, abstract, comment, review and editorial and 3) insufficient data. Articles published in a language other than English were also excluded.

Data Extraction {#s2c}
---------------

From each study, information like: author, year of publication, country of origin, cancer type, ethnicity, number of cases and controls, source of control groups (study design) and genotyping method was extracted. In some cases, identical data were described in more than one publication; in such cases the secondary studies were not included in the meta-analysis. In a few studies, part of the data had already been reported elsewhere, therefore, only the novel data was included. We also checked for HWE in control subjects among all publications.

Genotype and Allele Distributions {#s2d}
---------------------------------

Genotype distributions were extracted from the eligible publications for each polymorphism or computed from allele frequencies (if genotype frequencies were not reported) on the basis of sample size, assuming Hardy-Weinberg equilibrium (HWE).

Methodological Quality Assessment {#s2e}
---------------------------------

The quality of selected studies was evaluated by scoring according to a set of predetermined criteria. The categories in scoring system used for assessing study quality are summarized in [Table S1](#pone.0050966.s004){ref-type="supplementary-material"} [@pone.0050966-Guo1]. Quality scores ranged from 0 to 10 and studies were scored as "good" if the score was 8--10, "fair" if the score was 5--7 and "poor" if the score was \<4.

Statistical Analysis {#s2f}
--------------------

In the present meta-analysis, we investigated the potential association between the variant allele of miRNA polymorphisms and cancer risk. Also, analysis between the heterozygote, the homozygote and also in dominant and recessive models was done to estimate cancer risk. Stratified analyses were performed by tumor site, ethnicity and source of controls (hospital or population based). Other potentially relevant sub-group analyses such as age, sex and cancer subgroup could not reliably be investigated due to limited data availability. Between-study heterogeneity was evaluated with a χ^2^-based Q-test among the studies [@pone.0050966-Cochran1]. Heterogeneity was considered significant when P\<0.05. In case of no significant heterogeneity, point estimates and 95% CI was estimated using the fixed effect model (Mantel--Haenszel), otherwise, random effects model (DerSimonian Laird) was employed [@pone.0050966-Mantel1], [@pone.0050966-DerSimonian1]. The significance of overall odds ratio (OR) was determined by the Z-test. A χ^2^ test with one degree of freedom was performed in controls to observe deviation from HWE. Publication bias was weighted by Begg's funnel plot and Egger's linear regression method with P\<0.05 being considered statistically significant [@pone.0050966-Woolf1]. To assess the stability of the results, sensitivity analyses were performed. Each study in turn was removed from the total, and the remaining studies were reanalyzed. Moreover, sensitivity analysis was also performed, excluding studies whose allele frequencies in controls exhibited significant deviation from the HWE, given that the deviation may denote bias [@pone.0050966-Thakkinstian1]. The type I error rate was fixed at 0.05. All the p values were two sided and all the statistical tests were implemented using the Comprehensive Meta-analysis software (Version 2.0, BIOSTAT, Englewood, NJ).

Hardy--Weinberg Equilibrium Correction {#s2g}
--------------------------------------

For evaluating impact of HWE-deviated studies on point estimates in genotype based contrasts, ORs were corrected by using the HWE-predicted genotype count in controls instead of the observed counts, as recommended by Trikalinos et al. [@pone.0050966-Trikalinos1]; thereafter, they were incorporated in the sensitivity analysis.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

[Table 1](#pone-0050966-t001){ref-type="table"} and [Table S2](#pone.0050966.s005){ref-type="supplementary-material"} show the characteristics of eligible studies and genotype frequency distributions of studied miRNA SNPs included in the present meta-analysis. Fifty-three studies published between 2008 and August 2012 met our inclusion criteria with a total of 27573 cancer cases and 34791 controls. Two studies in Chinese language and 12 cohort studies were excluded from the present analysis. The total score of most studies was over 7 ([Table S3](#pone.0050966.s006){ref-type="supplementary-material"}). Thirty-two of the studies were conducted on subjects with Asian ethnicity (14689 cases/19894 controls) and 21 with Caucasian ethnicity (12884 cases/14897 controls). Malignances were histologically or pathologically confirmed in 35 of the included studies, while in 11 studies it was not defined. Controls in 19 studies were population-based, while controls of 31 studies were hospital-based. Two studies included both population-based and hospital-based controls while another 2 studies did not report about the control source. Twelve out of 53 studies did not report on the matching criteria for controls while other studies recruited controls corresponding to cases by the age/sex/area. A classical polymerase chain reaction--restriction fragment length-polymorphism (PCR--RFLP) method was adopted in 28 of the 53 studies. Seven studies used TaqMan assay; four studies used direct sequencing of the polymorphism; three studies used SNPlex; two studies used SNaPshot, Illumina's GoldenGate, high-resolution melting analysis (HRMA) and polymerase chain reaction--ligation detection reaction (PCR-LDR) assay each while 1 study each used fluorescence labeled hybridization (PCR-FRET), MALDI-TOF mass spectrometry, polymerase chain reaction with confronting two-pair primers (PCR-CTTP), Melting-temperature--shift allele-specific genotyping (Tm-shift) and Sequenom's MassARRAY as genotyping methods. The distributions of studied SNPs genotype in all the studies were in accordance with HWE in the control cohort, except for five studies [@pone.0050966-Okubo1]--[@pone.0050966-Ye1] ([Table 1](#pone-0050966-t001){ref-type="table"} footnote).

Quantitative Data Synthesis {#s3b}
---------------------------

### miR-146a rs2910164 {#s3b1}

The miR-146a rs2910164 polymorphism was analyzed in 27 studies with 12088 cases and 17340 controls and was not found to be associated with cancer risk (OR = 0.918, 95% CI = 0.777--1.086, *P*-value = 0.320; CC vs. GG; [Table 2](#pone-0050966-t002){ref-type="table"}). Significant heterogeneity was observed (*Q* = 77.126, *P* = \<0.001, *I^2^* = 66.289%, CC vs. GG). Similar results were obtained at the allelic level and for other genetic models also with significant heterogeneity (P~Het~ = \<0.001--0.008; [Table 2](#pone-0050966-t002){ref-type="table"}). After the exclusion of the study by George et al. [@pone.0050966-George1], whose genotypic distribution in controls deviated from HWE, the results did not significantly alter from the corresponding pooled OR (OR = 0.919, 95% CI = 0.775--1.090, *P*-value = 0.331; CC vs. GG). Removing 8 low score studies {[@pone.0050966-Okubo1], [@pone.0050966-George1], [@pone.0050966-Jazdzewski1]--[@pone.0050966-Kim1] with score ≤5}, did not altered the pooled results ([Table S4a](#pone.0050966.s007){ref-type="supplementary-material"}).

10.1371/journal.pone.0050966.t002

###### Meta-analysis of mir-146a rs2910164 polymorphism.

![](pone.0050966.t002){#pone-0050966-t002-2}

  Variables            n[a](#nt109){ref-type="table-fn"}    Cases/Controls   C-allele vs. G-allele   CC vs. GG        CG vs. GG        Dominant(CC+CG vs. GG)   Recessive(CC vs. CG+GG)                                                                
  ------------------ ------------------------------------- ---------------- ----------------------- ----------- --------------------- ------------------------ ------------------------- ------- --------------------- --------- --------------------- ---------
  **Cancer type**                                                                                                                                                                                                                                      
  Hepatocellular                       5                      1146/1510       1.102(0.981--1.237)      0.242     0.764(0.590--0.988)           0.313              1.087(0.899--1.314)     0.284   1.126(0.940--1.349)    0.229    1.148(0.939--1.403)    0.293
  Breast                               3                      2669/3395       1.023(0.945--1.107)      0.938     1.098(0.912--1.322)           0.539              0.989(0.887--1.103)     0.888   1.007(0.908--1.118)    0.955    1.094(0.920--1.300)    0.453
  Other                               19                      8273/12435      0.934(0.844--1.035)     \<0.001    0.913(0.727--1.146)          \<0.001             0.999(0.896--1.115)     0.002   0.985(0.877--1.106)   \<0.001   1.009(0.826--1.232)   \<0.001
  **Ethnicity**                                                                                                                                                                                                                                        
  Asian                               14                      5914/10118      0.889(0.785--1.007)     \<0.001    0.818(0.650--1.029)          \<0.001             0.972(0.891--1.060)     0.084   0.931(0.800--1.083)   \<0.001   0.925(0.770--1.112)   \<0.001
  Caucasian                           13                      6174/7222       1.050(0.993--1.111)      0.459     1.102(0.886--1.370)          \<0.001             1.046(0.974--1.124)     0.017   1.055(0.985--1.130)    0.114    1.274(1.096--1.481)    0.153
  **Study design**                                                                                                                                                                                                                                     
  Population based    9[\*](#nt110){ref-type="table-fn"}      5706/10226      1.015(0.898--1.147)      0.379     1.185(0.936--1.500)           0.008              1.070(0.990--1.156)     0.051   1.089(1.012--1.172)    0.265    1.331(1.076--1.645)    0.002
  Hospital based      17[\*](#nt110){ref-type="table-fn"}     6409/10606      0.893(0.799--0.997)     \<0.001    0.809(0.650--1.007)          \<0.001             0.950(0.878--1.029)     0.117   0.922(0.813--1.044)    0.002    0.922(0.762--1.115)   \<0.001

Random effects model was used when *P* value of Q for heterogeneity test (*P~Het~*)\<0.05; otherwise, fixed effect model was used.

Number of studies involved.

The study by Lung et al., [@pone.0050966-Lung1] has both hospital based and population based controls.

OR: odds ratio; CI: confidence interval.

Stratified analyses significantly reduced the heterogeneity of the subgroups. Based on different cancer types, non-significant increased risk was found in hepatocellular cancer (OR = 1.1--1.2; [Table 2](#pone-0050966-t002){ref-type="table"}) and borderline increased risk for breast cancer (OR∼1.0--1.1). However, no significant association was found in other cancers (including lung, gastric, cervical, esophageal, gallbladder, urinary bladder, prostate, head and neck, thyroid and glioma).

In the stratified analysis based on ethnicity of study population, there was a strong association between rs2910164 and overall cancer risk in Caucasian population under recessive model (OR = 1.274, 95%CI = 1.096--1.481, *P* = 0.002; *I^2^* = 28.99%). However, this association was lost in Asian populations ([Table 2](#pone-0050966-t002){ref-type="table"}). Further subgroup analysis demonstrated that the rs2910164 'C' allele was associated with significantly increased cancer risk in population based study design (OR = 1.1--1.3) ([Table 2](#pone-0050966-t002){ref-type="table"}).

### mir-196a2 rs11614913 {#s3b2}

Thirty studies investigated mir-196a2 rs11614913 polymorphism and its association with cancer (13703 cases and 15439 controls). The "T" allele of the polymorphism was considered as the variant allele in the present analysis. The overall OR showed statistically significant association between the rs11614913 polymorphism and reduced risk of cancer (OR = 0.846, 95% CI = 0.747--0.958, *P~Het~*\<0.001: TT vs. CC and OR = 0.941, 95% CI = 0.889--0.996, *P~Het~*\<0.001: T vs. C allele; [Table 3](#pone-0050966-t003){ref-type="table"}). After the exclusion of the study by George et al. [@pone.0050966-George1], whose genotypic distribution in controls deviated from HWE, the results did not significantly altered from the corresponding pooled OR (OR = 0.849, 95% CI = 0.749--0.962, *P*-value = 0.010: TT vs. CC). Removing low scoring studies did not make significant deviation from the above obtained results {[@pone.0050966-Okubo1], [@pone.0050966-George1], [@pone.0050966-Vinci1]--[@pone.0050966-Jedlinski1] ([Table S4b](#pone.0050966.s007){ref-type="supplementary-material"})}.

10.1371/journal.pone.0050966.t003

###### Meta-analysis of mir-196a2 rs11614913 polymorphism.

![](pone.0050966.t003){#pone-0050966-t003-3}

  Variables            n[a](#nt113){ref-type="table-fn"}    Cases/Controls   T-allele vs. C-allele   TT vs. CC        TC vs. CC        Dominant(TT+TC vs. CC)   Recessive(TT vs. TC+CC)                                                                  
  ------------------ ------------------------------------- ---------------- ----------------------- ----------- --------------------- ------------------------ ------------------------- --------- --------------------- --------- --------------------- ---------
  **Cancer type**                                                                                                                                                                                                                                        
  Breast                               5                      3449/4140       0.914(0.804--1.040)      0.020     0.812(0.607--1.085)           0.014              0.939(0.850--1.037)      0.532    0.911(0.829--1.000)    0.148    0.872(0.703--1.080)    0.027
  Lung                                 4                      2219/2232       0.893(0.821--0.971)      0.149     0.793(0.671--0.938)           0.259              0.927(0.801--1.074)      0.059    0.882(0.768--1.013)    0.075    0.842(0.737--0.962)    0.201
  Colorectal                           3                       951/1538       0.848(0.754--0.954)      0.223     0.690(0.543--0.876)           0.150              0.886(0.719--1.091)      0.636    0.813(0.667--0.990)    0.351    0.751(0.621--0.909)    0.209
  Hepatocellular                       4                       1015/999       0.862(0.683--1.088)      0.019     0.744(0.466--1.189)           0.022              0.897(0.721--1.115)      0.631    0.850(0.692--1.043)    0.190    0.809(0.567--1.154)    0.037
  Other                               14                      6069/6530       0.994(0.912--1.083)      0.001     0.915(0.744--1.124)          \<0.001             1.125(0.975--1.298)      0.001    1.080(0.941--1.240)   \<0.001   0.873(0.740--1.029)   \<0.001
  **Ethnicity**                                                                                                                                                                                                                                          
  Asian                               17                      7718/8580       0.905(0.845--0.969)      0.004     0.820(0.699--0.963)          \<0.001             0.983(0.866--1.116)      0.003    0.923(0.814--1.047)    0.001    0.831(0.748--0.923)    0.006
  Caucasian                           13                      5985/6859       0.994(0.908--1.088)      0.002     0.889(0.729--1.084)           0.002              1.056(0.944--1.183)      0.039    1.033(0.918--1.162)    0.010    0.889(0.741--1.067)    0.002
  **Study design**                                                                                                                                                                                                                                       
  Population based    12[\*](#nt114){ref-type="table-fn"}     6520/7355       0.901(0.833--0.975)      0.010     0.777(0.651--0.928)           0.003              0.946(0.877--1.021)      0.262    0.905(0.842--0.972)    0.136    0.812(0.693--0.952)    0.001
  Hospital based      18[\*](#nt114){ref-type="table-fn"}     7508/8421       0.945(0.873--1.022)     \<0.001    0.845(0.708--1.009)          \<0.001             1.032(0.910--1.170)     \<0.001   0.984(0.863--1.121)   \<0.001   0.854(0.755--0.965)    0.002

Random effects model was used when *P* value of Q-test for heterogeneity test (*P~Het~*)\<0.05; otherwise, fixed effect model was used.

Number of studies involved.

The study by Hoffman et al., [@pone.0050966-Hoffman1] has both hospital based and population based controls.

OR: odds ratio; CI: confidence interval.

Stratified analysis by cancer type showed that this association was significant in lung and colorectal cancer at the allelic and genotypic level (except TC vs. CC) ([Table 3](#pone-0050966-t003){ref-type="table"}). However, the association was lost under the dominant model in lung cancer. No significant association was found in other cancers (including gastric, cervical, esophageal, gallbladder, urinary bladder, prostate, head and neck and glioma).

In the stratified analysis by ethnicity, Asian individuals had lower risk of cancer under both the allelic and genotypic level (OR\<1.0), whereas Caucasian individuals did not show any significant association under any genetic model. Additional subgroup analysis significantly associated rs11614913 'T' allele with decreased cancer risk in population based study design (OR = 0.77--0.90) ([Table 3](#pone-0050966-t003){ref-type="table"}).

### mir-499 rs3746444 {#s3b3}

Fourteen studies evaluated mir-499 rs3746444 polymorphism and its association with cancer. There was a marginally increased overall risk of cancer under the allelic and genotypic models \[OR = 1.130, 95%CI = 1.002--1.275, *P* = 0.046, *I* ^2^ = 72.85% (C vs. T allele) and OR = 1.177, 95%CI = 1.007--1.377, *P* = 0.041, *I* ^2^ = 74.66% (CT vs. TT); [Table 4](#pone-0050966-t004){ref-type="table"}\]. After the exclusion of the study by George et al. [@pone.0050966-George1], whose genotypic distribution in controls deviated from HWE, the borderline significant association was lost (*P* = 0.066; allelic model). However, no association was found between genotype CC and cancer risk under the other models. Based on the ethnicity of study population, association was found in Asian populations under allelic and recessive models ([Table 4](#pone-0050966-t004){ref-type="table"}). Removing low scoring studies did not alter the above obtained results {[@pone.0050966-Okubo1], [@pone.0050966-George1], [@pone.0050966-Zhou1], [@pone.0050966-Xiang1], [@pone.0050966-Vinci1], [@pone.0050966-Kim1] ([Table S4c](#pone.0050966.s007){ref-type="supplementary-material"})}.

10.1371/journal.pone.0050966.t004

###### Meta-analysis of mir-499 rs3746444 polymorphism.

![](pone.0050966.t004){#pone-0050966-t004-4}

  Variables           n[a](#nt117){ref-type="table-fn"}   Cases/Controls   C-allele vs. T-allele   CC vs. TT        CT vs. TT        Dominant(CC+CT vs. TT)   Recessive(CC vs. CT+TT)                                                                  
  ------------------ ----------------------------------- ---------------- ----------------------- ----------- --------------------- ------------------------ ------------------------- --------- --------------------- --------- --------------------- -------
  **Cancer type**                                                                                                                                                                                                                                      
  Breast                              2                     2588/3260       1.115(0.878--1.417)      0.017     1.257(0.701--2.255)           0.036              1.067(0.952--1.196)      0.163    1.079(0.967--1.203)    0.056    1.111(0.869--1.421)   0.050
  Hepatocellular                      3                      436/784        1.134(0.641--2.006)      0.001     1.245(0.357--4.338)           0.023              1.001(0.762--1.314)      0.074    1.116(0.625--1.993)    0.009    1.515(0.839--2.734)   0.062
  Other                               9                     4117/4435       1.139(0.976--1.330)     \<0.001    1.074(0.875--1.320)           0.383              1.262(0.992--1.606)     \<0.001   1.175(0.948--1.456)   \<0.001   1.012(0.828--1.238)   0.130
  **Ethnicity**                                                                                                                                                                                                                                        
  Asian                               8                     3751/4343       1.227(1.006--1.497)     \<0.001    1.402(0.941--2.088)           0.037              1.210(0.972--1.506)     \<0.001   1.243(0.994--1.554)   \<0.001   1.357(1.062--1.734)   0.074
  Caucasian                           6                     3390/4136       0.989(0.916--1.067)      0.343     0.976(0.803--1.186)           0.875              1.140(0.895--1.451)      0.001    0.967(0.878--1.064)    0.237    0.936(0.773--1.132)   0.394
  **Study design**                                                                                                                                                                                                                                     
  Population based                    5                     4026/4726       1.037(0.961--1.119)      0.021     1.098(0.886--1.360)           0.126              1.027(0.935--1.128)      0.217    1.036(0.947--1.133)    0.065    1.086(0.879--1.342)   0.200
  Hospital based                      8                     3014/3624       1.206(0.926--1.570)     \<0.001    1.246(0.874--1.776)           0.045              1.369(1.017--1.844)     \<0.001   1.360(1.033--1.789)   \<0.001   1.113(0.763--1.624)   0.016

Random effects model was used when *P* value of Q-test for heterogeneity test (*P~Het~*)\<0.05; otherwise, fixed effect model was used.

Number of studies involved.

OR: odds ratio; CI: confidence interval.

### mir-149 rs2292832 {#s3b4}

Seven studies evaluated mir-149 rs2292832 and its association with cancer risk. The results of the overall meta-analysis did not suggest any association between rs2292832 and cancer susceptibility for all genetic models ([Table 5](#pone-0050966-t005){ref-type="table"}). Exclusion of the study by Vinci et al. [@pone.0050966-Vinci2] and Kim et al., [@pone.0050966-Kim1] with quality score of 2 did not altered the pooled estimate ([Table S4d](#pone.0050966.s007){ref-type="supplementary-material"}).

10.1371/journal.pone.0050966.t005

###### Meta-analysis of mir-149 rs2292832 polymorphism.

![](pone.0050966.t005){#pone-0050966-t005-5}

  Variables           n[a](#nt120){ref-type="table-fn"}   Cases/Controls   T-allele vs. C-allele   TT vs. CC        TC vs. CC        Dominant(TT+TC vs. CC)   Recessive(TT vs. TC+CC)                                                              
  ------------------ ----------------------------------- ---------------- ----------------------- ----------- --------------------- ------------------------ ------------------------- ------- --------------------- ------- --------------------- -------
  **Cancer type**                                                                                                                                                                                                                                  
  Breast                              2                     1254/1322       0.949(0.845--1.067)      0.167     0.931(0.709--1.222)           0.418              0.919(0.781--1.082)     0.106   0.921(0.789--1.077)   0.101   0.971(0.750--1.259)   0.737
  Other                               5                     2888/2920       1.018(0.938--1.103)      0.417     1.034(0.860--1.243)           0.205              1.018(0.904--1.146)     0.816   1.025(0.916--1.147)   0.591   1.066(0.915--1.241)   0.172
  **Ethnicity**                                                                                                                                                                                                                                    
  Asian                               5                     2932/2983       0.991(0.916--1.073)      0.418     1.003(0.838--1.200)           0.486              0.968(0.860--1.088)     0.314   0.978(0.875--1.094)   0.240   1.056(0.910--1.225)   0.499
  Caucasian                           2                     1210/1259       1.004(0.887--1.136)      0.094     0.993(0.742--1.328)           0.061              1.013(0.858--1.197)     0.658   1.009(0.861--1.182)   0.297   0.988(0.746--1.310)   0.068
  **Study design**                                                                                                                                                                                                                                 
  Population based                    4                     2562/2558       0.996(0.908--1.094)      0.324     0.980(0.815--1.179)           0.496              0.979(0.868--1.103)     0.275   0.990(0.883--1.110)   0.206   1.088(0.917--1.291)   0.409
  Hospital based                      2                     1579/1555       0.957(0.853--1.074)      0.688     1.016(0.670--1.539)           0.234              0.976(0.826--1.154)     0.323   0.960(0.819--1.124)   0.363   0.930(0.753--1.149)   0.742

Random effects model was used when *P* value of Q-test for heterogeneity test (*P~Het~*)\<0.05; otherwise, fixed effect model was used.

Number of studies involved.

OR: odds ratio; CI: confidence interval.

Through stratified analyses, no significant associations were found in any of the subgroups (racial descent, cancer types and study design) ([Table 5](#pone-0050966-t005){ref-type="table"}).

The effect of some polymorphisms could not be evaluated due to the limited number of studies (mir-27a rs895819 and mir-373 rs12983273 and rs10425222 = 3 studies; mir-100 rs1834306, mir-124-1 rs531564, mir-128 rs11134527, mir-155 rs928883 and rs2829803, mir-15a rs9535416 and rs2476391, mir-1792 rs17642969, mir-219 rs107822 and rs213210, mir-26a1 rs7372209, mir-30a rs1358379, mir-30c1 rs16827546, mir-335 rs3807348 and rs41272366, mir-423 rs6505162, mir-492 rs2289030, mir-604 rs2368392, mir-608 rs4919510 and mir-631 rs5745925 = 2 studies; mir-618 rs2682818, mir-605 rs2043556, mir-34b/c rs4938723, mir-126 rs4636297, let7f-2 rs17276588, let-7a3 rs731085, mir-101-1 rs7536540, mir101-2 rs17803780 and rs12375841 and mir-338 rs62073058 = 1 study each).

Sensitivity Analysis {#s3c}
--------------------

A single study involved in the meta-analysis was removed each time to reflect the influence of the individual data set to the pooled ORs for each of the studied miRNA polymorphisms. The corresponding pooled ORs were not significantly altered for any of the SNPs studied ([Table S5a](#pone.0050966.s008){ref-type="supplementary-material"}-d).

Publication Bias Analysis {#s3d}
-------------------------

Publication bias was assessed by performing funnel plot and Egger\'s regression test under all models. For mir-149 rs2292832, because the number of included studies was small, we did not perform publication bias analysis. After combining all the cancer types, a little asymmetry was observed for mir-146a rs2910164, but the results of Egger\'s regression test suggested no evidence for publication bias (Y axle intercept = -0.896, (95% CI) = −3.047 to 1.253; t = 0.859, *p* = 0.398 for allelic model) ([Figure S1](#pone.0050966.s001){ref-type="supplementary-material"}). Also, Begg and Mazumdar rank correlation test indicated absence of publication bias (*P* ~2tailed~ = 0.646). Similarly for mir-196a2 rs11614913 and mir-499 rs3746444, funnel plots were symmetrical and the Egger\'s test for both models showed no significance, suggesting little evidence of publication bias ([Figure S2](#pone.0050966.s002){ref-type="supplementary-material"} and [S3](#pone.0050966.s003){ref-type="supplementary-material"}).

A cumulative meta-analysis was also done by sorting the studies in the sequence of largest to smallest, and analysis performed with the addition of each study. The point estimate of the study did not deviate with the addition of smaller studies, ruling out the possibility of publication bias for all the analyzed miRNA SNPs.

Meta-analyses of Association Studies on miRNA SNPs {#s3e}
--------------------------------------------------

Eleven meta-analyses published in 2011 and 2012 were retrieved, focusing on 2 miRNA polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913). [Table 6](#pone-0050966-t006){ref-type="table"} shows the main characteristics of individual meta-analyses included. The number of primary studies included in the meta-analyses ranged from 4 to 27 with the number of subjects included spanning from 3007 to 10569. The results of the published meta-analyses of the association between miRNA SNPs and cancer showed an overall statistically significant increased risk for mir-196a2 rs11614913 (variant C allele). In subgroup analysis, the increased risk was more prominent in digestive system cancers such as breast, colorectal and hepatocellular cancer. For mir-146a rs2910164, in an overall analysis, no significant associations were found. However, in the stratified analysis, this polymorphism was associated with increased breast cancer risk among Europeans [@pone.0050966-Lian1] and negatively associated with digestive system cancer [@pone.0050966-Xu1]. The results are also consistent with the outcome from our present meta-analysis.

10.1371/journal.pone.0050966.t006

###### Description of meta-analyses included in the systematic review.

![](pone.0050966.t006){#pone-0050966-t006-6}

  S. no.                               Reference                               PublicationYear                            Cancer Type                             Cases/controls     miRNA     rs number    P~het~ [\*](#nt123){ref-type="table-fn"}   OR[\*](#nt123){ref-type="table-fn"}   95% CI[\*](#nt123){ref-type="table-fn"}
  -------- ------------------------------------------------------------------ ----------------- ---------------------------------------------------------------- ---------------- ----------- ------------ ------------------------------------------ ------------------------------------- -----------------------------------------
  1                        Lian et al., [@pone.0050966-Lian1]                       2012                                       BC                                   4238/4469      miR-146a    rs2910164                     0.757                                    1.16                                 0.98--1.36
  2                         Guo et al., [@pone.0050966-Guo1]                        2012                      HCC, CRC, GBC, PSCC, OSCC, ESCC, GC                   4999/7606      miR-196a2   rs11614913                    0.0003                                   1.38                                 1.13--1.67
  3         Xu et al., [@pone.0050966-Xu3] [\*](#nt123){ref-type="table-fn"}        2011                     BC, LC, PTC, HCC, GBC, HNSCC, PC, ESCC                 7183/7943      miR-146a    rs2910164                      0.03                                    0.89                                 0.75--1.05
                                                                                                                 BC, LC, GBC, Glioma, HNSCC, GC                     7992/8849      miR-196a2   rs11614913                     0.45                                    0.92                                 0.85--0.99
  4                        Wang et al., [@pone.0050966-Wang3]                       2012                         LC, BC, GC, Glioma, GBC, HNSCC                     6540/7562      miR-196a2   rs11614913                    0.021                                    1.18                                 1.01--1.39
  5                         Chu et al., [@pone.0050966-Chu3]                        2011                 BC, ESCC, LC, GC, HCC, GBC, PC, HNSCC, Glioma              9341/10569     miR-196a2   rs11614913                   \<0.001                                   1.22                                 1.04--1.44
  6                         Gao et al., [@pone.0050966-Gao1]                        2011                                       BC                                   3007/3718      miR-146a    rs2910164                      0.65                                    0.90                                 0.75--1.07
                                                                                                                                                                    3287/4298      miR-196a2   rs11614913                     0.03                                    1.30                                 1.01--1.68
  7                         Qiu et al., [@pone.0050966-Qiu1]                        2011           BC, UBC, ESCC, OC, CCGBC, GC, HCC, LC, PTC, HNSCC, Glioma       10585/12183     miR-146a    rs2910164                    \<0.001                                   1.13                                 0.93--1.37
  8                         Qiu et al., [@pone.0050966-Qiu2]                        2011         BC, UBC, ESCC, OC, CCGBC, GC, HCC, LC, PTC, HNSCC, Glioma, CRC    10441/12353     miR-196a2   rs11614913                   \<0.001                                   1.30                                 1.14--1.48
  9                       Zhang et al., [@pone.0050966-Zhang3]                      2012                LC, HCC, BC, CRC, GC, ESCC, GC, Glioma, UBC, PC            10435/12075     miR-196a2   rs11614913                   \<0.001                                   1.23                                 1.08--1.39
  10                       Wang et al., [@pone.0050966-Wang4]                       2012               BC, GC, PC, UBC, CC, ESCC, OC, HCC, PTC, RCC, GBC           10496/12885     miR-146a    rs2910164                      0.09                                    1.16                                 0.98--1.38
  11                       Wang et al., [@pone.0050966-Wang5]                       2012                          LC, GC, CRC, GBC, HCC, ESCC                       2394/2767      miR-146a    rs2910164                      0.02                                    1.17                                 0.95--1.44

BC: breast cancer; GBC: gallbladder cancer; GC: gastric cancer; LC: lung cancer; PC: prostate cancer; HNSCC: head and neck squamous cell carcinoma; PTC: papillary thyroid carcinoma; ESCC: esophageal squamous cell carcinoma; HCC: hepatocellular cancer; CRC: colorectal cancer; OSCC: oral squamous cell carcinoma; PSCC: pharynx squamous cancer; OC: ovarian cancer; CC: cervical cancer; RCC: renal cell cancer.

Considered T allele as variant allele as in the present study.

P~het~, *p*-value for heterogeneity.

OR, odds ratio.

CI, confidence interval.

Homozygous wild vs. homozygous variant genotype.

We also computed the population-attributable risk (PAR) to refer to the proportion of disease risk in Caucasians and Asians that can be attributed to the causal effects of the risk SNP (variant genotype). PAR can be assessed by using the formula [@pone.0050966-Greenland1]: PAR (%) = (OR-1)/OR × (number of exposed cases/total number of cases) × 100%, where OR is the pooled OR stratified for ethnicity derived from the meta-analyses incorporating the largest number of individuals. The results showed mir-196a2 rs11614913 to be the most impacting polymorphism (which might account for approximately 15% among Asians) \[PAR (%) mir-196a2 rs11614913 'T' allele carriers: Asians = 14.9, Caucasians = 1.4\]. Although the ORs and allele frequencies used for computing PAR were taken from the same ethnic group, the results could still be biased due to the difference in geographic areas and population stratification in individual studies. A more consistent estimation of the PAR requires additional statistics to identify population subgroups significantly affected by particular miRNA polymorphism.

Discussion {#s4}
==========

In the present study, we reviewed the available literature on genetic studies of miRNA SNPs in cancer and conducted four independent meta-analyses for association between overall cancer and mir-146a rs2910164, mir-196a2 rs11614913, mir-149 rs2292832 and mir-499 rs3746444 polymorphisms. Our results associated mir-196a2 rs11614913 with a decreased overall cancer risk. Meanwhile, there was no association between other studied miRNA SNPs. However, due to the small number of studies with an overall mediocre quality and lack of confirmatory studies, it is very difficult to draw any definitive conclusions.

miR-146a, first found in mouse, has been shown to play an important role in tumorigenesis by promoting cell proliferation and colony formation in NIH/3T3 cells [@pone.0050966-Xu2]--[@pone.0050966-LagosQuintana1]. It has also been shown to play an important role in suppressing metastatic ability in breast cancer, prostate cancer and MDA-MB-231 cells [@pone.0050966-Bhaumik1]--[@pone.0050966-Lin1]. A 'G' to 'C' substitution (rs2910164) located in the middle of the stem hairpin on the passenger strand of the precursor of miR-146a has a lower transcriptional activity due to decreased nuclear pri-miR-146a processing efficiency leading to low levels of mature miR-146a in cells with homozygous variant genotype (CC) [@pone.0050966-Jazdzewski1]. Also, the change decreases free energy (dG) from -42.40 kcal/mol for G allele to -39.60 kcal/mol for C allele, signifying a less stable secondary structure for the C allele compared with the G allele ([Table S6](#pone.0050966.s009){ref-type="supplementary-material"}). No significant association between this polymorphism and overall cancer risk was found in our meta-analysis replicating a previous meta-analysis study [@pone.0050966-Xu1]. However, the variation was associated with increased cancer risk in Caucasians and studies with population based design. This could be explained on the fact that most of the population based studies were in Caucasian population.

Aberrant mir-196a2 expression is implicated in cancer susceptibility and metastasis in several malignancies [@pone.0050966-Xu3], [@pone.0050966-Tian1]. Human miR-196a2 comprises two different mature miRNAs (miR-196a and miR196a\*) processed from same stem-loop. The rs11614913 polymorphism lies in the mature sequence of miR-196a\* and negatively impacts endogenous processing of either miRNA precursor to its mature form [@pone.0050966-Hoffman2] and is associated with various malignancies [@pone.0050966-Tian1], [@pone.0050966-Hu1]. The rs11614913 'C' allele increases the expression levels of mature hsa-mir-196a2 compared to 'T' allele and the SNP also affects the binding of mature hsa-miR-196a2 to its target mRNA [@pone.0050966-Hu1].We observed that there was a significantly decreased risk of overall cancer with this polymorphism at allelic and recessive level as with previous studies [@pone.0050966-Guo1], [@pone.0050966-Xu1], [@pone.0050966-Chu2], [@pone.0050966-Wang1]. When stratified by cancer types, the association was found in lung and colorectal cancer only which might be caused by the different microenvironments and mechanisms in different cancer types.

The mir-499 microRNA has also been implicated in several human malignancies ([Table S1](#pone.0050966.s004){ref-type="supplementary-material"}). A T\>C (rs3746444) polymorphism has been identified in the stem region of the mir-499 gene resulting in A:U to G:U mismatch in the stem structure of miR-499 precursor. This SNP has been shown to be associated with risk for various cancers as evident from association studies ([Table S1](#pone.0050966.s004){ref-type="supplementary-material"}), however the mechanism remains unknown. This polymorphism increased the risk of cancer in the dominant genetic model. The association was significant with hepatocellular cancer in Asians, which demonstrates that Asian populations with this polymorphism might be more susceptible to hepatocellular cancer compared to Europeans. Moreover, the population attributable risk (PAR) for this polymorphism was also around 15% among Asians, signifying its importance.

For mir-149 rs2292832, no statistical association was found in the overall comparison and subgroup analysis. Because of the limited number of studies (7) for this polymorphism, the results should be interpreted with caution.

For other miRNA polymorphisms, because of limited number of studies (ranging from one to three), meta-analysis was not done as it would not have been reliable.

One of the important concerns in every meta-analysis is publication bias. Because meta-analysis reviews quantitative data from numerous studies, the publication bias effect of the literature incorporated in the study can bias the meta-analytic outcome. In the present study, the funnel plot for overall results was symmetrical for all the analyzed miRNA SNPs, indicating negligible likelihood of publication bias. The Egger's test and Begg and Mazumdar rank correlation test were also negative for publication bias. However, the possibility of publication bias cannot completely be ruled out [@pone.0050966-Peters1]. Sensitivity analyses using HWE-adjusted ORs and corresponding variances also did not modify the results.

To the best of our knowledge, the present study is the most comprehensive meta-analysis to date to have assessed the relationship between the miRNA polymorphisms and cancer risk. Nevertheless, our meta-analysis had some limitations common to these types of studies. First, the present meta-analysis only included case-control studies, most of which were hospital based and excluded 12 cohort studies to avoid potential heterogeneity in comparing results. Thus, the controls may not reflect the representative element of the source population. Second, the difference in the geographic areas (environmental factors) and genetic backgrounds of the study cohort in each article could influence the results. Third, the low sample size in some of the included studies might influence the statistical power to better evaluate the association between miRNA polymorphisms and overall cancer, especially in subgroup analysis. Fourth, gene-gene and gene-environment interactions were not analyzed which might alter the associations between miRNA gene polymorphisms and cancer. Also, a more precise analysis stratified by variables such as age, sex etc. could not be performed due to limitations of the data which also restricted our ability to detect possible sources of heterogeneity.

In conclusion, the results of our meta-analysis demonstrate that mir-196a2 rs11614913 polymorphisms have significant associations with overall cancer risk, although some results are limited by the small number of studies. However, no significant association exists between mir-146a rs2910164, mir-499 rs3746444 and mir-149 rs2292832 and overall cancer. Further studies with a large sample size are needed to evaluate their association with cancer risk.
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**Begg's funnel plot of publication bias for miR-146a rs2910164.** Log OR is plotted versus standard error of Log OR for each included study. Every circle dot represents a separate study for the indicated association (C versus G).
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**Begg's funnel plot of publication bias for mir-196a2 rs11614913.** Log OR is plotted versus standard error of Log OR for each included study. Every circle dot represents a separate study for the indicated association (TT versus CC).
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**Begg's funnel plot of publication bias for mir-499 rs3746444.** Log OR is plotted versus standard error of Log OR for each included study. Every circle dot represents a separate study for the indicated association (CC versus TT).
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